ReviR Therapeutics received an undisclosed amount of funding to advance its pipeline of disease-modifying RNA-targeting therapies for the treatment of Huntington’s disease and Charcot-Marie-Tooth disease, both rare neurological disorders.
All entries for: ReviR Therapeutics
April 1, 2026
ReviR Therapeutics
Orphan Drug Designation
treatment of vanishing white matter disease
Disease Area: Rare Diseases